Table 4

Review and comparison of the major clinical manifestations, treatment and outcome of BL
Authors Country/Region Number Age (years) M :F Abdomen (%) H & N (%) LN (%) CNS (%) Treatment Os or EFS (years)
Reiter A (1995) [23] Germany 152 0-17 3.6:1 / / / 4 BFM 86 EFS 79 %(1y)
EFS 79 %(2y)
Ertem U (1996) [24] Turkey 63 3-14 2:1 96.8 15.9 ≤3.2 % 7.9 Ziegler’s and intensive protocol* Os 60.0 %(1y)
Os 57.8 %(2y)
Cario MS (2003) [7] USA 470 0-21 3.7:1 / / / 12 COMP/LSA2L2 Os 70.0 (1y)
COMP/D-COMP EFS 60.0 %(1y)
CCG-552 Os 64.5 % (2y)
Orange/French** EFS 58.5 %(2y)
Boerma EG (2004) [25] Netherlands 66 0-15 4.5:1 >42 9 20 / / /
Hassan R (2008) [13] Brazil 54 2-14 2:1 72 2 11 4 / /
Chuang SS (2008) [3] Taiwan 17 0-16 1.8:1 41.2 41.2 17.6 11.8 CHOP(−like) Os 80 %(1y)
Modified BFM regimen Os 66.7 % (2y)
Mbulaiteye SM (2009) [26] USA 296 0-14 3.7:1 21 9 56 / /
The current study China 43 0-18 9.75:1 46.5 32.6 16.3 9.3 CHOP(−like) /Hyper-CVAD/ Os 39.5 %(1y)
LMB/ HD-MTX + Ara-c Os 39.5 %(2y)

* Eight drug intensive protocol, generated a favorable outcome than Ziegler’s protocol.

** A protocol with Short and intensive therapy, including intensified methotrexate and Ara-C, was associated with a significant improvement in long-term EFS (80 ± 6 %).

Bi et al.

Bi et al. Diagnostic Pathology 2012 7:72   doi:10.1186/1746-1596-7-72

Open Data